VMAT for early pancreatic adenocarcinoma in case where surgery is contraindicated
Main Article Content
Abstract
There are several methods for managing pancreatic cancer. Surgical resection gives the best chance for a possible cure in the early stages of the disease. However only 10-20% of patients present with potentially resectable pancreatic cancer. Chemotherapy is the treatment of choice for the advanced metastatic disease. For locally advanced, inoperable pancreatic cancer, combined chemotherapy and radiation is the preferred treatment.1 In the case of patients who have contraindications for surgery, concurrent chemoradiation may be chosen2. The patient in this study, was a case of adenocarcinoma at the pancreatic head, stage T1N0M0, with underlying heart disease; she thus was contraindicated for a major operation. The treatment plan was chemoradiation, using VMAT radiotherapy technique with a radiation dose of 45Gy in 25 fractions and oral Xeloda.
Article Details
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
2. https://www.elekta.com/assets/vmat/case_studies/0781% 2009-08%20VMAT%20Seattle.pdf
3. https://www.isrrt.org/images/isrrt/Astro_WhitePaper_ Singles_release.pdf
4. Boggula F, Lorenz F, Muller L, et al. Experimental validation of 3D dose verification system for intensities modulated arc therapies Phys. Med. Bio. Oct 2010;7;55 (19):5619-5633